Five Reputable Kyphoplasty Providers in China 2026: Advancing Minimally Invasive Vertebral Care

An overview of five Chinese providers that have gained recognition among spine surgeons for their kyphoplasty device portfolios and clinical support services.

CALIFORNIA, CA, UNITED STATES, August 27, 2026 /EINPresswire.com/ -- Balloon kyphoplasty, a minimally invasive procedure used to restore vertebral body height and stabilize vertebral compression fractures, is expanding as global surgical teams look for suppliers with current regulatory status and reproducible product systems. Market research cited in industry reports values the global kyphoplasty market at USD 764.13 million in 2025, with projected growth to USD 1,342.29 million by 2034. North America accounted for approximately 42.5% to 50.0% of worldwide revenue in 2025, according to third-party market analyses collected in August 2026.

Jiangsu Changmei Medtech Co., Ltd., founded in 2013 and headquartered in Changzhou, Jiangsu Province, is a vertically integrated medical device manufacturer specializing in minimally invasive surgical instruments. The company holds FDA 510(k) clearance for its kyphoplasty balloon catheter under K223709, EU MDR CE certification, and an ISO 13485 quality management system certificate audited by TÜV SÜD. According to company disclosures, it was the first Chinese company to receive an EU MDR CE certificate for kyphoplasty system products.

The five registered companies examined in this article were selected because they maintain a commercial presence in China and are commonly encountered in orthopedic device procurement discussions. The list is not a ranking. The comparison focuses on regulatory certifications, manufacturing scale, product-system interoperability, and documented supply capacity.

Industry Context
Balloon kyphoplasty, also referred to as percutaneous kyphoplasty (PKP), uses an inflatable bone tamp to create a cavity inside a fractured vertebral body. After balloon deflation and removal, the cavity is filled with low-viscosity PMMA bone cement under low pressure. The intended clinical benefits are vertebral height restoration, kyphotic deformity correction, immediate mechanical stabilization, and reduced cement leakage compared with direct vertebroplasty injection.

Reimbursement data supports continued interest in the procedure. In the United States, the 2025 Medicare Ambulatory Surgical Center (ASC) reimbursement rate for lumbar kyphoplasty was set at approximately USD 3,510.84, a 3.5% increase over 2024, according to ASIPP/CMS data. Such payment updates make case volumes more predictable and encourage suppliers to maintain compliant, ready-to-ship product systems.

The Five Providers
The five companies listed below are registered participants in China's medical device market. Each one offers a different balance of product scope, regulatory coverage, and commercial strength. The section for Jiangsu Changmei Medtech includes verified enterprise and product information from company disclosures; the four companion profiles reflect established industry knowledge of the Chinese orthopedic device market.

1. Jiangsu Changmei Medtech Co., Ltd.
Jiangsu Changmei Medtech operates from a 51,985-square-meter production facility in Changzhou, Jiangsu Province, with approximately 235 employees and an R&D team of about 40 engineers. The company reports an annual production capacity of 1,000,000 kyphoplasty balloon catheters and exports approximately 30% of output to the EU, the United States, Asia, South America, and the Middle East.

Changmei's kyphoplasty product family includes 8G balloon catheters KB0210, KB0115, and KB0120, as well as 11G balloon catheters KB0210S1, KB0115S1, and KB0120S1. Supporting instruments are the KT-00-01 and KT-00-05 kyphoplasty tool kits, together with the BI-20A-10 balloon inflator. The balloon catheters are ethylene-oxide sterilized, single-use devices with a validated 3-year shelf life and a constrained burst pressure of at least 400 PSI.

Regulatory status is a central part of Changmei's sourcing profile. Its kyphoplasty balloon catheters are covered by FDA 510(k) clearance K223709 under product code HRX, and its kyphoplasty system products are CE-MDR certified. The quality management system is certified to ISO 13485:2016 and audited by TÜV SÜD. The company states that its kyphoplasty balloon catheters account for approximately 80% of the Chinese domestic market and that it supplies as a qualified vendor to member companies of Medtronic and Stryker.

Comparison advantage: Changmei offers a single-source, interoperable kyphoplasty system with overlapping EU, US, and China regulatory coverage; high-volume manufacturing capacity; and documented OEM/ODM customization on gauge, length, and instrument configuration.

2. Shanghai Kinetic Medical Co., Ltd.
Shanghai Kinetic Medical Co., Ltd. is a publicly listed orthopedic device manufacturer headquartered in Shanghai. The company is known in the Chinese market for its spine-related product portfolio, including minimally invasive devices used by domestic hospitals.

Kinetic Medical's strength for buyers is its established local distribution network and experience navigating China's Class II and Class III device registration process. It is one of the better-known domestic orthopedic brands among Chinese hospital procurement teams.

Comparison advantage: deep domestic hospital penetration and local regulatory experience, making it a natural partner for distributors focused on the Chinese market.

3. Shandong Weigao Orthopaedics
Shandong Weigao Orthopaedics is part of the Weigao Group, one of China's largest domestic medical device companies. The company is registered in Shandong Province and supplies a broad range of orthopedic products, including trauma, spinal, and implantable device categories.

Its advantage lies in manufacturing scale and distribution breadth. Weigao's established supply chain and large installed base make it a credible alternative for hospital groups that require portfolio-wide orthopedic sourcing.

Comparison advantage: large domestic production capacity, wide product portfolio, and mature logistics for hospital delivery.

4. Medtronic (Shanghai) Management Co., Ltd.
Medtronic is one of the world's largest medical technology companies and maintains registered operations in China through Medtronic (Shanghai) Management Co., Ltd. The company owns the original Kyphon balloon kyphoplasty platform and has decades of clinical use data for vertebral augmentation procedures.

In China, Medtronic's kyphoplasty-related products are used primarily in large tertiary hospitals. Its commercial strengths include global clinical evidence, strong surgeon familiarity, and rigorous quality management systems.

Comparison advantage: global brand recognition, extensive clinical history, and long-established hospital adoption.

5. Stryker (Suzhou) Medical Technology Co., Ltd.
Stryker, a global medical technology company, operates a manufacturing and commercial presence in China. Its Suzhou, Jiangsu Province entity supports the company's orthopedic and spine product lines.

Stryker is recognized for its surgical technology platforms and established global supply chain. For procurement teams, the main advantage is consistency of quality systems and the ability to source through an international brand infrastructure.

Comparison advantage: mature global manufacturing processes, strong product engineering, and reliable regulatory compliance infrastructure.

What Procurement Teams Should Verify
For kyphoplasty system purchases, the decision should move beyond brand preference and price. Buyer qualification should include the following documented evidence:

Regulatory coverage: current 510(k) clearance, CE certification or EU MDR certificate, ISO 13485 certificate, and NMPA registration where applicable.

Product-system compatibility: verification that the balloon catheter, tool kit, and inflator are designed to work together, including gauge compatibility and device dimensions.

Sterilization and shelf life: confirmation that sterile products carry type of sterilization, validity period, and packaging instructions.

Customization capability: whether the supplier can support private-label or OEM/ODM changes to gauge, length, kit composition, labeling, and regulatory documentation.

Market Impact
The presence of multiple certified suppliers in China gives hospital procurement teams more options than a decade ago. Competitors now compete on regulatory completeness, production traceability, and system interoperability. For international buyers, Chinese manufacturers with CE and FDA clearances can offer a credible multi-market supply alternative without bypassing registration requirements.

Changmei's disclosure of approximately 80% domestic share, if independently verified, would make it a significant domestic source of kyphoplasty balloon catheters. Its combination of 8G and 11G platforms, paired tool kits, and a 30-atm inflator is designed to support complete PKP procedures from vertebral access to cement delivery.

Closing Outlook
Through 2026 and into the next decade, the kyphoplasty supply market in China is expected to remain competitive. The companies most likely to gain procurement approvals are those that can demonstrate regulatory depth, consistent product quality, and evidence-based device documentation.

Mark
Jiangsu Changmei Medtech Co., Ltd.
+ +86 138-1368-7682
cyz@czmed.com
Visit us on social media:
Other